ArticleRheumatology international2025
Radiological extent predicts prognosis and relapse after acute exacerbation of interstitial lung disease in patients with rheumatoid arthritis: KEIO-RA-cohort.
Article in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical variables and quantitative CT radiomics for mortality risk stratification after acute exacerbation of idiopathic inflammatory myopathy-associated interstitial lung disease.Frontiers in immunology · 2026Article
- The association of symptoms, pulmonary function test and computed tomography in interstitial lung disease at the onset of connective tissue disease: an observational study with artificial intelligence analysis of high-resolution computed tomography.Rheumatology international · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To clarify how the extent of radiological interstitial lung abnormalities impacts the prognosis and risk of relapse in patients with rheumatoid arthritis (RA) following acute exacerbation of interstitial lung disease (AE-ILD). We conducted a retrospective review of all consecutive RA patients from the KEIO-RA cohort who experienced AE-ILD during 2012 to 2024. We investigated the association between the extent of abnormalities on high-resolution computed tomography (HRCT) images, as assessed by Goh's criteria, and outcomes in patients who survived AE-ILD versus those who did not, as well as between patients who survived AE-ILD without relapse and those who experienced relapse. Out of the 34 cases, 10 (29.4%) patients died due to AE-ILD. Of the 26 cases who survived the first AE-ILD event, 8 (30.8%) experienced a relapse, and 2 of them died. Non-survivors had higher Goh's HRCT scores both before and at the time of AE-ILD compared to survivors. Patients who experienced relapse had higher HRCT scores after AE-ILD compared to those who did not relapse. There were no significant differences in treatment regimens for AE-ILD, titers for anti-cyclic citrullinated peptide antibody or rheumatoid factor, or arthritis activity among the groups. Higher HRCT scores both before and at the time of AE-ILD are associated with increased mortality risk, while elevated scores after AE-ILD are linked to a higher likelihood of relapse. These findings highlight the critical role of HRCT assessment in guiding prognosis and post-AE-ILD management in patients with RA.
Indexed as
Identifiers
40192850What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.